Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director | June 08, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,389 |
Ending reported balance
After 2026-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-08 · Exercise / conversion · Acquired 1,429 · Balance 31,032 F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2026-06-10 · Sale · Disposed 643 · Balance 30,389 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $245.17 and $253.04. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-08 · Exercise / conversion · Disposed 1,429 · Balance 0 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 403,856 |
Reported balance
Holding disclosure · report date 2026-06-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 403,856 F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.
F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $245.17 and $253.04.
F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 643 | $249.00 | $160,107.00 |
DisclosureSEC source: 0001193125-26-266433 · ownership.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,389 F3 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4 · shares: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $245.17 and $253.04. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionRestricted Stock Units · Derivative | 1,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266433 · ownership.xml · derivative · entry 4 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 1,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-266433 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:18 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 1,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-264041 · ownership.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,721 Underlying: Common Stock · 1,721 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant. Read SEC document |
| June 02, 2026 Filed Jun 2, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 5,537 | $223.39 | $1,236,910.43 |
DisclosureSEC source: 0001193125-26-254038 · ownership.xml · nonDerivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,603 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $221.82 and $225.21. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 6,000 | $230.30 | $1,381,800.00 |
DisclosureSEC source: 0001193125-26-254038 · ownership.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,140 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $229.56 and $232.14. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 6,000 | $233.46 | $1,400,760.00 |
DisclosureSEC source: 0001193125-26-254038 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,140 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $231.50 and $235.23. Read SEC document |
| February 26, 2026 Filed Feb 28, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 25,000 | $161.11 | $4,027,750.00 |
DisclosureSEC source: 0001193125-26-083587 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,140 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.33 and $162.26. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001193125-26-072481 · ownership.xml · derivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,721 Underlying: Common Stock · 6,250 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 6,250 | $4.95 | $30,937.50 |
DisclosureSEC source: 0001193125-26-072481 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 00:23 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,485 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001193125-26-064681 · ownership.xml · derivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,971 Underlying: Common Stock · 12,485 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 00:23 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 12,485 | $4.95 | $61,800.75 |
DisclosureSEC source: 0001193125-26-064681 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 00:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,193 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001193125-26-045110 · ownership.xml · derivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,193 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 00:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 5,193 | $8.02 | $41,647.86 |
DisclosureSEC source: 0001193125-26-045110 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 00:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 488 | $127.40 | $62,171.20 |
DisclosureSEC source: 0000950170-25-113874 · ownership.xml · nonDerivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,212 F1 · kind: Represents the open market purchase of shares of the Issuer's common stock. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 00:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 287 | $127.30 | $36,535.10 |
DisclosureSEC source: 0000950170-25-113874 · ownership.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,724 F1 · kind: Represents the open market purchase of shares of the Issuer's common stock. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 00:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 800 | $127.20 | $101,760.00 |
DisclosureSEC source: 0000950170-25-113874 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,437 F1 · kind: Represents the open market purchase of shares of the Issuer's common stock. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 1,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084560 · ownership.xml · derivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429 Underlying: Common Stock · 1,429 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant, June 6, 2026. F3 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant, June 6, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 3,166 | $0.00 Strike: $111.91 | $0.00 |
DisclosureSEC source: 0000950170-25-084560 · ownership.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,166 Underlying: Common Stock · 3,166 shares Expires 2035-06-06 F1 · derivative.exercise_date: The options vest in full on the one-year anniversary of the date of grant, June 6, 2026. Read SEC document |
| May 28, 2025 Filed May 29, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 3,750 | $103.43 | $387,862.50 |
DisclosureSEC source: 0000950170-25-079229 · ownership.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,637 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $102.71 and $104.38. Read SEC document |
| May 27, 2025 Filed May 29, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 3,750 | $105.47 | $395,512.50 |
DisclosureSEC source: 0000950170-25-079229 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,387 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $104.75 and $106.50. Read SEC document |
| May 20, 2025 Filed May 21, 2025 01:46 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 3,000 | $107.49 | $322,473.00 |
DisclosureSEC source: 0000950170-25-075539 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,137 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $107.34 and $107.65. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:06 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,127 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002052 · ownership.xml · derivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,127 shares Expires 2025-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options prior to expiration for cash and hold of underlying shares. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:06 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 9,127 | $9.00 | $82,143.00 |
DisclosureSEC source: 0000950170-25-002052 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options prior to expiration for cash and hold of underlying shares. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,410 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0000950170-24-129330 · ownership.xml · derivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,410 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options prior to expiration for cash and hold of underlying shares. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 33,410 | $5.94 | $198,455.40 |
DisclosureSEC source: 0000950170-24-129330 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock options prior to expiration for cash and hold of underlying shares. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:31 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 5,799 | $0.00 Strike: $73.90 | $0.00 |
DisclosureSEC source: 0000950170-24-071964 · ownership.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,799 Underlying: Common Stock · 5,799 shares Expires 2034-06-07 F1 · derivative.exercise_date: The options vest in full on the one-year anniversary of the date of grant, June 7, 2025. Read SEC document |
| May 29, 2024 Filed May 30, 2024 00:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 5,248 | $75.14 | $394,332.62 |
DisclosureSEC source: 0000950170-24-066175 · ownership.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,600 F1 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F2 · kind: Represents the sale of underlying shares of previously exercised stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $75.00 and $75.90. Read SEC document |
| May 28, 2024 Filed May 30, 2024 00:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 5,249 | $75.21 | $394,774.67 |
DisclosureSEC source: 0000950170-24-066175 · ownership.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,848 F1 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F2 · kind: Represents the sale of underlying shares of previously exercised stock options. F3 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $75.00 and $75.88. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,016 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-23-049648 · doc4.xml · derivative · entry 4 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,016 shares Expires 2024-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 18,572 | $75.18 | $1,396,189.10 |
DisclosureSEC source: 0001209191-23-049648 · doc4.xml · nonDerivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 403,856 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F4 · ownership.nature: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 11,016 | $75.19 | $828,241.26 |
DisclosureSEC source: 0001209191-23-049648 · doc4.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,097 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 11,016 | $3.67 | $40,428.72 |
DisclosureSEC source: 0001209191-23-049648 · doc4.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 22:21 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 5,681 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001209191-23-034847 · doc4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,681 Underlying: Common Stock · 5,681 shares Expires 2033-06-02 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 2, 2024. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:13 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 2,870 | $0.00 Strike: $65.32 | $0.00 |
DisclosureSEC source: 0001209191-23-016455 · doc4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,870 Underlying: Common Stock · 2,870 shares Expires 2033-03-01 F1 · shares: Represents 2,870 options elected to be received in lieu of cash compensation earned in 2022. All of such options are immediately exercisable. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,501 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001209191-23-000870 · doc4.xml · derivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,501 shares Expires 2023-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options and hold of underlying shares. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:11 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 17,501 | $1.30 | $22,751.30 |
DisclosureSEC source: 0001209191-23-000870 · doc4.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options and hold of underlying shares. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:07 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 16,976 | $0.00 Strike: $25.53 | $0.00 |
DisclosureSEC source: 0001209191-22-034820 · doc4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,976 Underlying: Common Stock · 16,976 shares Expires 2032-06-03 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 3, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 11:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,496 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001209191-22-019403 · doc4.xml · derivative · entry 3 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,501 Underlying: Common Stock · 3,496 shares Expires 2023-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options and hold of underlying shares. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 11:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 3,496 | $1.30 | $4,544.80 |
DisclosureSEC source: 0001209191-22-019403 · doc4.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options and hold of underlying shares. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 2,798 | $0.00 Strike: $29.91 | $0.00 |
DisclosureSEC source: 0001209191-22-017156 · doc4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,798 Underlying: Common Stock · 2,798 shares Expires 2032-03-03 F1 · shares: Represents 2,798 options elected to be received in lieu of cash compensation earned in 2021. All of such options are immediately exercisable. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 12:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 1,021 | $35.10 | $35,837.10 |
DisclosureSEC source: 0001209191-21-066004 · doc4.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 422,428 F1 · ownership.nature: Such shares were purchased by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 12:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 409 | $35.07 | $14,343.63 |
DisclosureSEC source: 0001209191-21-066004 · doc4.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 421,407 F1 · ownership.nature: Such shares were purchased by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:51 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 7,325 | $0.00 Strike: $61.32 | $0.00 |
DisclosureSEC source: 0001209191-21-038952 · doc4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,325 Underlying: Common Stock · 7,325 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 4, 2022. Read SEC document |
| May 12, 2021 Filed May 13, 2021 11:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 500 | $58.15 | $29,075.00 |
DisclosureSEC source: 0001209191-21-032250 · doc4.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 420,998 F1 · ownership.nature: Such shares were purchased by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:45 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 1,201 | $0.00 Strike: $65.02 | $0.00 |
DisclosureSEC source: 0000899243-21-010805 · doc4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201 Underlying: Common Stock · 1,201 shares Expires 2031-03-04 F1 · shares: Represents 1,201 options elected to be received in lieu of cash compensation earned in 2020. All of such options are immediately exercisable. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 00:43 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GiftCommon Stock | 397,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009208 · edgar.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Whale Island, LP Disclosed balance after: 397,998 F1 · kind: The reporting person transferred these shares to a family limited partnership, Whale Island LP, of which the reporting person is the sole general partner and of which the reporting person and his three children are the sole limited partners. Each of the reporting person's children have a 1% pecuniary interest in Whale Island LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 00:43 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GiftCommon Stock | 397,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009208 · edgar.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 F1 · kind: The reporting person transferred these shares to a family limited partnership, Whale Island LP, of which the reporting person is the sole general partner and of which the reporting person and his three children are the sole limited partners. Each of the reporting person's children have a 1% pecuniary interest in Whale Island LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 12:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 650 | $78.50 | $51,025.00 |
DisclosureSEC source: 0001104659-20-078441 · a4.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,698 F1 · balance_after: 250,000 shares were previously transferred to the reporting person's former spouse for no consideration pursuant to a property settlement agreement entered into in connection with a divorce proceeding. The reporting person no longer reports as beneficially owned any securities owned by his former spouse. Read SEC document |
| June 05, 2020 Filed Jun 5, 2020 22:40 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001179110-20-007056 · edgar.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-06-05 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 5, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.